BCL-2 Inhibitor ABT-737 Effectively Targets Leukemia-Initiating Cells with Differential Regulation of Relevant Genes Leading to Extended Survival in a NRAS/BCL-2 Mouse Model of High Risk-Myelodysplastic Syndrome
BCL-2 抑制剂 ABT-737 可有效靶向白血病起始细胞，对相关基因进行差异调节，从而延长高风险骨髓增生异常综合征 NRAS/BCL-2 小鼠模型的生存期
期刊:International Journal of Molecular Sciences
影响因子:0.7
doi:10.3390/ijms221910658
Petra Gorombei, Fabien Guidez, Saravanan Ganesan, Mathieu Chiquet, Andrea Pellagatti, Laure Goursaud, Nilgun Tekin, Stephanie Beurlet, Satyananda Patel, Laura Guerenne, Carole Le Pogam, Niclas Setterblad, Pierre de la Grange, Christophe LeBoeuf, Anne Janin, Maria-Elena Noguera, Laure Sarda-Mantel, P
